08/21/2025
"One challenge with this drug is some eye-related side effects like blurry vision. But giving it less frequently lowers this risk. Many patients, especially those not eligible for CAR T, could benefit from Blenrep (belantamab mafodotin) given every 8 to 12 weeks."